If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
902.00    17.00 (1.92%)
Bid:
901.00
Ask:
903.00
Spread: 2.00 (0.222%)
Market Cap: £1.25b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Replacement - Director/PDMR Shareholding

29 Apr 2026 15:04

RNS Number : 4489C
Savills PLC
29 April 2026
 

The following amendment has been made to the Director/PDMR Shareholding announcement released on 29 April 2026 at 13:23:26 under RNS #4417C:

 

The date of the vesting (28 April 2026) of Deferred Share Awards has been added to the introductory paragraph.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

SAVILLS PLC (THE "COMPANY")

TRANSACTION IN SHARES BY DIRECTORS AND PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

 

Vesting of Deferred Share Awards

 

Awards over ordinary shares of the Company under the Company's Deferred Share Plans have become unconditional in all respects following the end of their Deferred Period. In satisfaction of the Awards, the Trustees of the Group's Employee Benefit Trusts have effected the transfer of shares on 28 April 2026, following the settlement of associated tax liabilities through the sale of shares, to Directors and PDMRs of the Company as follows:

 

Director/ PDMR

Number of shares transferred

Number of shares disposed to cover tax liabilities associated with award vesting

Shareholding following this notification

Shareholding as a % of issued share capital

Simon Shaw (Director)

48,468

43,468

(shares sold to cover tax liabilities associated with award vesting only)

276,793

0.19%

Martin Fidden (PDMR)

8,664

-

34,046

0.02%

Alex Jeffrey (PDMR)

53,143

-

292,074

0.20%

Chris Lee (PDMR)

9,774

8,710

(shares sold to cover tax liabilities associated with award vesting only)

133,311

0.09%

Raymond Lee (PDMR)

35,671

-

211,852

0.14%

David Lipson (PDMR)

30,333

-

175,760

0.12%

James Sparrow (PDMR)

42,767

38,106

(shares sold to cover tax liabilities associated with award vesting only)

170,884

0.12%

 

The share price on disposal of all shares was £8.405 per share.

 

 

 

 

Grant of Deferred Share Awards

 

The Company announces that on 28 April 2026 the grant of the share-based element of 2025 profit share awards has been made under The Savills Deferred Share Bonus Plan to Directors and PDMRs as follows:

 

Director/ PDMR

Number of shares subject to The Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on 28 April 2026

Simon Shaw (Director)

111,077

Chris Lee (PDMR)

22,155

David Lipson (PDMR)

9,105

James Sparrow (PDMR)

63,832

These awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Period to reflect final and interim dividends declared during the Deferred Period.

 

The Company also announces that on 28 April 2026 the grant of an award has been made under The Savills Deferred Share Plan (No.2 Plan) to the following PDMR:

PDMR

Number of shares subject to The Savills Deferred Share Plan (No.2 Plan) awarded to the PDMR on 28 April 2026

Martin Fidden (PDMR)

119,758

13% of the above award has a Deferred Period of two years51% of the above award has a Deferred Period of three years36% of the above award has a Deferred Period of four years

70% of the award with a Deferred Period of three years and 100% of the award with a Deferred Period of four years is subject to the satisfaction of performance criteria relating to the financial performance of the Savills Asia Pacific ex-Greater China business over 2025 to 2027 (inclusive).

All tranches of the award are subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Periods to reflect final and interim dividends declared during the Deferred Periods.

 

The Company also announces that on 28 April 2026 the grant of an award has been made under The Schedule to The Savills Deferred Share Plan (No.2 Plan) to a PDMR based in the United States of America as follows:

 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 28 April 2026

David Lipson (PDMR)

44,214

One-third of Mr Lipson's award will vest on each of the three anniversaries subsequent to the date of grant subject to continued employment and performance. The award is subject to rolled-up dividend shares whereby the number of shares awarded will be increased during the Deferred Period to reflect final and interim dividends declared during the Deferred Periods.

 

Resulting beneficial interests under The Savills Deferred Share Bonus Plan and The Savills Deferred Share Plan (No.2 Plan) further to the above notifications are as follows:

Director/ PDMR

Resulting beneficial interest under The Savills Deferred Share Bonus Plan and The Savills Deferred Share Plan (No.2 Plan)

Simon Shaw (Director)

237,302

Martin Fidden (PDMR)

65,870

Alex Jeffrey (PDMR)

75,287

Chris Lee (PDMR)

48,348

David Lipson (PDMR)

105,062

James Sparrow (PDMR)

138,914

 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

 

(a)

Name

1. Simon Shaw

2. Martin Fidden

3. Alex Jeffrey

4. Chris Lee

5. Raymond Lee

6. David Lipson

7. James Sparrow

 

2.

Reason for the notification

 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Chief Executive Officer - Asia Pacific (ex-Greater China)/ PDMR

3. Chief Executive Officer - Savills Investment Management/ PDMR

4. Group Legal Director & Company Secretary/ PDMR

5. Chief Executive - Hong Kong, Macau and Greater China/ PDMR

6. Chief Executive Officer - Savills North America/ PDMR

7. Chief Executive Officer - UK & EMEA/ PDMR

 

(b)

Initial notification/ Amendment

 

Initial notification

3.

Details of the issuer

 

(a)

Name

Savills plc

 

(b)

LEI

213800WXICGMBWHTA933

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

(a)

Description of the Financial Instrument

 

Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

 

GB00B135BJ46

(c)

Nature of the transaction

 

1) Vesting of awards under the Company's Deferred Share Plans and sale of shares to cover tax liabilities associated with award vesting only

2) Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Plans

 

(d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

1)

Acquisition

£nil per share

 

 

 

 

 

Disposal (to cover tax liabilities associated with award vesting only)

£8.405 per share

1. 92,253

2. 8,664

3. 53,143

4. 18,484

5. 35,671

6. 30,333

7. 80,873

 

1. 43,468

2. n/a

3. n/a

4. 8,710

5. n/a

6. n/a

7. 38,106

 

2)

£nil per share

1. 111,077

2. 119,758

3. n/a

4. 22,155

5. n/a

6. 53,316

7. 63,832

 

(e)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

 

 

(f)

Date of the transaction

 

28 April 2026

(g)

Place of the transaction

 

Vesting of awards - Outside a trading venue

 

Sale of shares to cover tax liabilities associated with award vesting only - London Stock Exchange

 

Grant of awards - Outside a trading venue

 

 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

 

29 April 2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUKRSRNUUSUAR
Date   Source Headline
14th Mar 20247:00 amRNSFinal Results
13th Mar 20241:37 pmRNSDirector/PDMR Shareholding
15th Feb 202410:00 amRNSBlock listing Interim Review
13th Feb 20246:07 pmRNSDirector/PDMR Shareholding
1st Feb 202411:00 amRNSTotal Voting Rights
22nd Jan 20249:11 amRNSBlock listing Interim Review
11th Jan 20244:02 pmRNSDirector/PDMR Shareholding
11th Jan 20247:00 amRNSYear End Trading Update
2nd Jan 202412:33 pmRNSTotal Voting Rights
15th Dec 202310:00 amRNSAdditional Listing
14th Dec 202312:56 pmRNSDirector/PDMR Shareholding
13th Dec 202311:42 amRNSNon-Executive Director Appointment
13th Nov 20232:02 pmRNSSAVILLS APPOINTS NEW CEO OF SAVILLS NORTH AMERICA
13th Nov 202312:00 pmRNSDirector/PDMR Shareholding
2nd Nov 20233:16 pmRNSForm 8.3 - OntheMarket PLC
1st Nov 202310:00 amRNSTotal Voting Rights
27th Oct 202310:00 amRNSAdditional Listing
12th Oct 20233:41 pmRNSDirector/PDMR Shareholding
2nd Oct 20238:50 amRNSTotal Voting Rights
22nd Sep 202311:00 amRNSAdditional Listing
12th Sep 20235:10 pmRNSTotal Voting Rights
1st Sep 202311:00 amRNSTotal Voting Rights
18th Aug 20232:00 pmRNSAdditional Listing
15th Aug 20234:06 pmRNSBlock listing Interim Review
14th Aug 20232:05 pmRNSDirector/PDMR Shareholding
10th Aug 20237:00 amRNSChair Succession
10th Aug 20237:00 amRNSHalf-year Report
21st Jul 202310:00 amRNSBlock listing Interim Review
11th Jul 202312:50 pmRNSDirector/PDMR Shareholding
4th Jul 20239:20 amRNSTotal Voting Rights
13th Jun 20235:31 pmRNSDirector/PDMR Shareholding
1st Jun 202310:00 amRNSTotal Voting Rights
17th May 20234:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
11th May 20236:12 pmRNSDirector/PDMR Shareholding
2nd May 20237:00 amRNSTotal Voting Rights
28th Apr 20234:07 pmRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSDirector/PDMR Shareholding
24th Apr 20235:15 pmRNSDirector/PDMR Shareholding
12th Apr 20232:30 pmRNSDirector/PDMR Shareholding
3rd Apr 20235:15 pmRNSAnnual Report and AGM Notice
30th Mar 20237:47 amRNSAdditional Listing
16th Mar 20237:00 amRNSFinal Results
14th Mar 20235:07 pmRNSHolding(s) in Company
13th Mar 202311:06 amRNSDirector/PDMR Shareholding
1st Mar 202310:00 amRNSTotal Voting Rights
16th Feb 202311:17 amRNSBlock listing Interim Review
13th Feb 20234:32 pmRNSDirector/PDMR Shareholding
23rd Jan 202312:45 pmRNSBlock listing Interim Review
12th Jan 20234:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.